Background: Follicular lymphoma (FL) is a chronic and incurable disease requiring multiple lines of therapy for patients (pts) with relapsed/refractory (R/R) disease. Covalent Bruton tyrosine kinase inhibitors (cBTKi) have transformed the management of select B-cell malignancies, in particular chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). However, despite the transformative impact in CLL and MCL, the efficacy of single-agent cBTKi has been limited in pts with R/R FL, with an overall response rate (ORR) of 20.9% to 37.5% (Gopal et al, J Clin Oncol, 2018; Bartlett et al, Blood, 2018). Pirtobrutinib, a highly selective, non-covalent (reversible) BTKi, inhibits both wildtype and C481-mutant BTK with equal low nM potency and has a favorable oral pharmacology that enables continuous BTK inhibition throughout the once-daily dosing interval. Pirtobrutinib has demonstrated promising efficacy and tolerability in pts with poor-prognosis B-cell malignancies following prior therapy, including cBTKi. Here, we report the safety and efficacy of pirtobrutinib in a cohort of pts with R/R FL from the BRUIN study (NCT03740529).
Methods: Pts with previously treated B-cell malignancies were eligible for treatment with pirtobrutinib monotherapy in either the dose escalation or expansion portion of the multicenter phase 1/2 BRUIN study. FL diagnosis required pathologic review of an adequate biopsy. Key endpoints included investigator-assessed ORR per Lugano 2014 criteria, duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety. A data cutoff date of 05 May 2023 was utilized.
Results: Among the 48 pts with FL, 45 (94%) pts received the recommended phase 2 dose of pirtobrutinib (200 mg once daily) as their starting dose. Pts had a median age of 64.5 years (range, 37.0-85.0), were mostly male (60%, n=29), and had a median of 3 (range, 1-12) prior lines of therapy. Most pts (81%, n=39) had Ann Arbor stage III/IV disease. The Follicular Lymphoma International Prognostic Index (FLIPI) risk was low (0-1) in 9 (19%) pts, intermediate (2) in 13 (27%) pts, high (3-5) in 23 (48%) pts, and missing in 3 (6%) pts. Overall, 43 (90%) pts had received chemotherapy plus an anti-CD20 antibody, 17 (35%) pts had received a PI3K inhibitor, 14 (29%) pts had received lenalidomide, 6 (13%) pts had received an autologous stem cell transplant, and 4 (8%) pts had received CAR T-cell therapy. Of the 4 (8%) pts who had received a prior cBTKi, 3 discontinued due to disease progression and 1 discontinued for intolerance. The ORR was 50.0% (95% confidence interval [CI], 35.2-64.8), including 7 (14.6%) complete responses and 17 (35.4%) partial responses (Figure). An additional 12 (25.0%) pts had stable disease. Among 4 pts who had received prior cBTKi, 3 achieved partial response and 1 had stable disease. With a median follow-up of 18.4 months (interquartile range, 10.1-21.0) among 24 responding pts, median DoR was 5.5 months (95% CI, 3.7-not estimable [NE]), and the 18-month estimated DoR rate was 41.0% (95% CI, 20.1-60.9). Median PFS was 5.8 months (95% CI, 3.8-8.1), and the 18-month estimated PFS rate was 32.3% (95% CI, 19.1-46.2). Median OS was NE, and the 18-month estimated OS rate was 78.3% (95% CI, 62.1-88.1). The efficacy outcomes by FLIPI risk category are presented in the Table. The median time on treatment was 7.6 months (range, 0.6-42.2), with 14 (29.2%) pts still receiving pirtobrutinib. The most frequent treatment-emergent adverse events (TEAEs), regardless of attribution, were diarrhea (29.2%, n=14), fatigue (25.0%, n=12), and nausea (22.9%, n=11). TEAEs of hemorrhage/hematoma (6.3%, n=3), hypertension (4.2%, n=2), and atrial fibrillation/flutter (2.1%, n=1) were infrequent. The most frequent grade ≥3 TEAEs were infection (18.8%, n=9) and neutropenia/neutrophil count decreased (14.6%, n=7). Only 1 (2.1%) pt had a treatment-related adverse event (rash) that led to pirtobrutinib discontinuation.
Conclusions: In this cohort of heavily pre-treated pts with R/R FL, pirtobrutinib showed potential efficacy and was well tolerated, including in pts with high risk FLIPI.
OffLabel Disclosure:
Shah:LOXO-Lilly: Consultancy, Other: Travel support; Novartis: Consultancy; TG therapeutic: Consultancy; Umoja: Consultancy; Epizyme: Consultancy; Janssen: Consultancy; Tundra Therapeutics: Current holder of stock options in a privately-held company; BMS/Juno: Consultancy; Seattle Genetics: Consultancy; Gilead/Kite: Consultancy; Incyte: Consultancy; Abbvie: Consultancy; Lilly Oncology: Consultancy, Research Funding; Miltenyi Biotec: Consultancy, Other: Travel support, Research Funding. Zinzani:JANSSEN-CILAG: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; BEIGENE: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; ASTRAZENECA: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; ROCHE: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; KYOWA KIRIN: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; NOVARTIS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; MSD: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; EUSAPHARMA: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; SANDOZ: Membership on an entity's Board of Directors or advisory committees; INCYTE: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; SECURA BIO: Membership on an entity's Board of Directors or advisory committees; CELLTRION: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; ADC THERAPEUTICS: Membership on an entity's Board of Directors or advisory committees; TAKEDA: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; SERVIER: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; GILEAD: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; BMS: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Wang:Anticancer Association: Honoraria; DTRM Biopharma (Cayman) Limited: Consultancy; Deciphera: Consultancy; Bristol Myers Squibb: Consultancy, Honoraria; BioInvent: Consultancy, Honoraria, Research Funding; BeiGene: Consultancy, Honoraria, Research Funding; Be Biopharma: Consultancy; AstraZeneca: Consultancy, Honoraria, Other: Travel, Research Funding; Amphista Therapeutics Limited: Consultancy; ADC Therapeutics America: Consultancy; Acerta Pharma: Consultancy, Honoraria, Research Funding; AbbVie: Consultancy, Honoraria; Genentech: Consultancy, Research Funding; InnoCare: Consultancy, Research Funding; Vincerx: Research Funding; Molecular Templates: Research Funding; Loxo Oncology: Consultancy, Research Funding; Genentech: Consultancy, Research Funding; Juno Therapeutics: Research Funding; WebMD: Honoraria; Celgene: Other: Travel, Research Funding; Studio ER Congressi: Honoraria; Practice Point Communications (PPC): Honoraria; Scripps: Honoraria; Physicians Education Resources (PER): Honoraria, Other: Travel; OncLive: Honoraria; Oncology Specialty Group: Honoraria; Nurix: Honoraria; NIH: Honoraria; Moffit Cancer Center: Honoraria; MJH Life Sciences: Honoraria; Medscape: Honoraria; Meeting Minds Experts: Honoraria; IDEOlogy Health: Honoraria; i3Health: Honoraria; Genmab: Honoraria, Research Funding; Dava Oncology: Honoraria, Other: Travel; Eastern Virginia Medical School: Honoraria; CAHON: Honoraria; Bantam Pharmaceutical: Honoraria; VelosBio: Consultancy, Research Funding; Pharmacyclics: Consultancy, Honoraria, Research Funding; Pepromene Bio: Consultancy; Parexel: Consultancy; Oncternal: Consultancy, Research Funding; Milken Institute: Consultancy; Miltenyi Biomedicine: Consultancy; Merck: Consultancy, Honoraria; Eli Lilly and Company: Consultancy, Research Funding; Leukemia & Lymphoma Society: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Kite, a Gilead Company: Consultancy, Honoraria, Other: Travel, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; MD Education: Honoraria; BGICS: Honoraria; Clinical Care Options: Honoraria; Epizyme: Consultancy, Honoraria; Hebei Cancer Prevention Federation: Honoraria; Imedex: Honoraria; TS Oncology: Honoraria; Mumbai Hematology Group: Honoraria; OMI: Honoraria; Pharmacyclics: Honoraria; Physicians Education Resources: Honoraria; Practice Point Communications: Honoraria; CSTone: Consultancy. Nasta:ADC Therapeutics: Honoraria; Merck-Data Safety Monitoring Committee: Membership on an entity's Board of Directors or advisory committees; Ono Pharmaceutical: Research Funding; Millennium Takeda: Research Funding; Loxo/Lilly: Research Funding; Accrotech: Honoraria; Genentech/Roche: Research Funding; Raphael: Research Funding; Pharmacyclics: Research Funding. Ogawa:Janssen Pharmaceuticals: Research Funding; IQVIA: Research Funding. Fakhri:Genmab/Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS/Juno: Consultancy, Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Consultancy, Membership on an entity's Board of Directors or advisory committees; ADC Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees; Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; BeiGene: Consultancy, Membership on an entity's Board of Directors or advisory committees; Genetech: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; LOXO/Lilly: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pharmacyclics: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding. Kuss:Roche,: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; AstraZeneca: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; CSL: Consultancy, Honoraria; Gilead: Consultancy, Honoraria. Patel:Kite: Consultancy, Research Funding, Speakers Bureau; Loxo Oncology: Consultancy, Research Funding; Pharmacyclics/Janssen: Consultancy, Research Funding; Nurix: Research Funding; MEI Pharma: Consultancy, Research Funding; TG Therapeutics: Consultancy, Speakers Bureau; Caribou Biosciences: Consultancy; Bristol Myers Squibb: Consultancy, Research Funding, Speakers Bureau; CRISPR Therapeutics: Research Funding; Morphosys: Consultancy; Trillium Therapeutics/Pfizer: Consultancy, Research Funding; BeiGene: Consultancy; Curis, Inc: Research Funding; Xencor: Consultancy, Research Funding; Sunesis Pharmaceuticals: Research Funding; Merck: Consultancy, Research Funding; Epizyme: Consultancy, Research Funding; Fate Therapeutics: Research Funding; Genentech/Roche: Consultancy, Research Funding; AstraZeneca: Consultancy, Research Funding, Speakers Bureau; ADC Therapeutics: Consultancy; Adaptive Biotechnologies: Research Funding; Abbvie: Consultancy. Coombs:Janssen: Honoraria; Octapharma: Consultancy; BeiGene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Genentech: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; AstraZeneca: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; TG Therapeutics: Honoraria; Bluebird Bio: Current equity holder in publicly-traded company; MEI Pharma: Honoraria; Mingsight: Honoraria; Loxo Oncology/Eli Lilly and Company: Consultancy, Honoraria, Research Funding. Ma:Janssen Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Juno/BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Genentech: Consultancy; BeiGene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; AstraZeneca: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Abbvie: Consultancy, Research Funding; Eli Lilly and Company/Loxo Oncology: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau. Patel:Janssen Oncology: Honoraria; Olema Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; ION Pharmaceuticals: Other: Leadership. Tessoulin:Incyte: Honoraria; Abbvie: Honoraria; Kite: Honoraria; Gilead: Honoraria. Stathis:AstraZeneca: Other: travel grant, Research Funding; Bayer: Consultancy, Research Funding; Eli Lilly and Company: Consultancy; Incyte: Other: travel grant, Research Funding; Janssen: Consultancy; AbbVie: Research Funding; ADC Therapeutics: Research Funding; Amgen: Research Funding; Cellestia: Research Funding; Loxo Oncology: Research Funding; Merck/MSD: Research Funding; Novartis: Research Funding; Pfizer: Research Funding; Philogen: Research Funding; Roche: Consultancy, Research Funding. Kim:Kyowa-Kirin: Research Funding; Sanofi: Research Funding; BeiGene: Research Funding; Boryong: Research Funding; F. Hoffmann-La Roche Ltd: Research Funding; Donga: Research Funding. Ennishi:Kyowa Hakko Kirin Co., Ltd.: Honoraria; BMS: Honoraria; Ono Pharmaceutical: Honoraria; Janssen: Honoraria; Incyte: Honoraria; Eisai: Honoraria, Research Funding; Chugai: Honoraria, Research Funding; Nippon Shinyaku Co.: Honoraria, Research Funding. Hashimoto:Ono Pharma: Honoraria; Janssen Pharma: Honoraria; Kyowa-Kirin: Honoraria; Chugai Pharmaceutical: Honoraria; LUCA Science: Patents & Royalties; Daiichi Sankyo Inc: Honoraria; Astellas Pharma: Honoraria. Kojima:Asahi Kasei Pharma Corporation: Research Funding; Kyowa Kirin Co., Ltd.: Research Funding; Janssen Pharmaceutical KK: Honoraria; Mochida Pharmaceutical Co.: Research Funding; Daiichi-Sankyo Co., Ltd: Research Funding; Eisai Co., Ltd.: Research Funding; Nippon Kayaku Co.,Ltd.: Research Funding; Sumitomo Pharma Co., Ltd.: Research Funding; Chugai Pharmaceutical Co., Ltd.: Research Funding; AstraZeneca KK: Honoraria; AbbVie GK: Honoraria. Zelenetz:Pharmacyclics: Consultancy, Honoraria; BeiGene: Consultancy, Honoraria, Research Funding; MEI Pharma Inc: Consultancy, Honoraria, Research Funding; Abbvie: Research Funding; Gilead: Consultancy, Honoraria; BMS: Consultancy, Honoraria; None other than mutual funds (401K): Current equity holder in publicly-traded company; F. Hoffmann-La Roche Ltd: Consultancy, Honoraria, Research Funding; SAB: Membership on an entity's Board of Directors or advisory committees; Janssen Pharmaceuticals: Consultancy, Honoraria; AstraZeneca: Consultancy, Honoraria; Lymphoma Research Foundation: Membership on an entity's Board of Directors or advisory committees. Cohen:Lam Therapeutics: Research Funding; BMS/Celgene: Research Funding; Takeda,: Research Funding; Novartis: Research Funding; BioInvent: Research Funding; Genentech: Research Funding; ADCT: Consultancy; Loxo/Lilly: Consultancy, Research Funding; AstraZeneca: Consultancy, Research Funding; Abbvie: Consultancy; Janssen: Consultancy; BeiGene: Consultancy. Vose:Eli Lilly and Company; Epizyme, Kite, Loxo, Novartis: Research Funding; AbbVie, MEI Pharma: Consultancy. Maddocks:AstraZeneca: Consultancy, Research Funding; AbbVie: Consultancy; BMS: Consultancy, Research Funding; Celgene: Consultancy, Research Funding; ADC Therapeutics: Consultancy; Incyte: Consultancy, Honoraria; Genentech: Consultancy; GenMab: Consultancy; Janssen: Consultancy, Honoraria; Morphosys: Consultancy; Pharmacyclics: Consultancy, Research Funding; Gilead/Kite: Consultancy; BeiGene: Consultancy; Epizyme: Consultancy; Eli Lilly and Company: Consultancy; Seattle Genetics: Consultancy; Novartis: Research Funding; Merck: Research Funding. Munir:Sobi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AstraZeneca: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Alexion: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; BeiGene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Abbvie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau. Sun:Eli Lilly and Company: Current Employment, Current equity holder in publicly-traded company. Bian:Eli Lilly and Company: Current Employment, Current equity holder in publicly-traded company. Tsai:Eli Lilly and Company: Current equity holder in publicly-traded company; Loxo@Lilly: Current Employment. Abada:Eli Lilly and Company: Current Employment, Current equity holder in publicly-traded company. Cheah:Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: TRAVEL, ACCOMMODATIONS, EXPENSES, Research Funding; MSD: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Gilead: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Ascentage Pharma: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; AstraZenecca: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Eli Lilly and Company: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; TG therapeutics: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; BeiGene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; AbbVie: Research Funding; Menarini: Consultancy, Honoraria; Genmab: Consultancy, Honoraria; Daizai: Consultancy, Honoraria; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees.
Pirtobrutinib is approved in the USA for treatment of relapsed or refractory MCL after at least 2 lines of systemic therapy, including prior BTKi.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal